Cigna's pharmacy benefits company, Evernorth, reached pricing deals with Eli Lilly and Novo Nordisk to reduce expenses and provide wider employer access to GLP-1 weight-loss treatments Wegovy and Zepbound.

A new study shows that people Zepbound lost about 50% more weight than those using Wegovy. It was the first head-to-head trial of the blockbuster weight-loss medications.

Cigna will cap out-of-pocket costs at $200 per month for patients using the weight-loss drugs Wegovy and Zepbound through an add-on to its pharmacy benefit management plans, the company announced on Wednesday.